No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook
Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...
Insider Monkey on MSN10d
Why Moderna Inc. (MRNA) Crashed Last Week
In this article, we are going to take a look at where Moderna Inc. (NASDAQ ... saying that data on mRNA vaccines sent by the ...
Barchart on MSN1d
Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?
Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
AOL7d
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
Kennedy Jr., a vocal vaccine skeptic ... HHS said its award to Moderna was, in part, to “enhance mRNA platform capabilities.” “The award made today is part of the ASPR’s commitment ...
Morningstar7d
Moderna is counting on its product pipeline to resuscitate its ailing stock
The COVID vaccine Spikevax is one of Moderna's two approved products ... and Human Services award of $211 million to enhance mRNA platform capabilities to help the U.S. better respond to emerging ...
Insider Monkey13d
Why Moderna, Inc. (MRNA) Is Among the Best Healthcare Stocks To Buy According to Analysts
Furthermore, the success of cancer vaccines provides a transformative ... a wide range of medical needs. Moderna, Inc. (NASDAQ:MRNA) operates as a tech-driven platform, using its innovative ...
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...